On the 14st of December, 2017 in Moscow the bilateral Russian-British forum “Health and Life”, organized by the Sechenov First Moscow State Medical University and the British Embassy in the Russian Federation took place in Moscow.
Vitaly Omelyanovskiy, the General Director of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, spoke about the prospects or the of the HTA development (in accordance with the Russian legislation of the comprehensive assessment) for medical devices and biomedical products. Special attention was paid to the assessment of innovative medicines and the system of their price regulation. According to prof. Omelyanovskiy, the pricing system should be linked to the result of a comprehensive assessment, especially for new drugs. This is the problem that should be solved in order to expand patients’ access to innovative medications, as well as improve the decision-making process to include drugs in restrictive lists for rational spending of budget funds.
The forum has become the effective platform for successful interaction between the two countries in sharing best practices in healthcare reform, pharmacy, digital medicine, science and education.